Abemaciclib - OmicsDI

Show results for

Unknown (385)
Genomics (140)
Transcriptomics (61)
Proteomics (11)
Metabolomics (8)
Other (4)
Clinical (2)
Models (1)
Multiomics (1)

Organisms

Homo sapiens (85)
Mus musculus (10)
Schizophyllum commune H4-8 (8)
Mycobacterium tuberculosis SP7 (8)
Oryza sativa Japonica Group (8)
Crotalus durissus terrificus (8)
Eriocheir sinensis (8)
Candidatus Endoriftia persephonae (8)
Mycobacterium tuberculosis SP10 (8)
Mycobacterium tuberculosis SP13 (8)
Cotesia typhae (8)
Mycobacterium tuberculosis SP22 (8)
Enterobacter ludwigii (8)
Corynebacterium diphtheriae bv. mitis str. ISS 3319 (8)
Chlamydomonas reinhardtii (8)
Lama (8)
Pyricularia oryzae P131 (8)
Enterococcus mundtii CRL35 (8)
Pongo pygmaeus (8)
Oncorhynchus tshawytscha (8)
Pseudomonas canadensis (8)
Strongylocentrotus purpuratus (8)
Influenza A virus (A/California/04/2009(H1N1)) (8)
Salmonella enterica subsp. enterica serovar Typhimurium (8)
Homo (8)
Bradyrhizobium diazoefficiens (8)
Streptococcus pyogenes STAB901 (8)
Pseudomonas aeruginosa PAO1H2O (8)
Megoura viciae (8)
synthetic construct (1)

Organisms

Homo sapiens (95)
Mus musculus (9)
Rattus norvegicus (1)

Repository

ENA (114)
geo (84)
MetaboLights (8)
pride (8)
EGA (4)
biostudies-arrayexpress (2)
iProX (2)
BioModels (1)
EVA (1)
jPOST (1)
LINCS (1)

Tissue

Epithelial cell (2)
Cell culture (2)
Myeloblast (1)
B-lymphocyte (1)
Malignant cell (1)
Breast (1)
Kidney cell (1)
Bone marrow (1)
Macrophage (1)
Primary cell (1)
Lung (1)
Permanent cell line cell (1)
Kidney (1)
B cell (1)
Blood cell (1)
Blood (1)

Disease

Breast cancer (4)
Carcinoma (1)
Neoplasms (1)
Lymphoma (1)
Lung cancer (1)
Acute myeloid leukemia (1)

Technology Type

Mass Spectrometry (8)
Mass spectrometry (5)
Mass spectrometry assay (3)
Bottom-up proteomics (3)
Data-independent acquisition (2)
Shotgun proteomics (2)
ILLUMINA, Illumina HiSeq 2000 (1)
KINOMEscan (1)
Fluorescence intensity (1)
Top-down proteomics (1)
Affinity purification coupled with mass spectrometry proteomics (1)

Instrument Platform

Liquid Chromatography MS - negative - reverse phase (4)
Liquid Chromatography MS - positive - reverse phase (4)
Liquid Chromatography MS - negative - hilic (2)
Liquid Chromatography MS - positive - hilic (2)
NextSeq 2000 (1)
Illumina HiSeq 2500 (1)
Illumina HiSeq 2000 (1)
Liquid Chromatography MS - alternating - reverse-phase (1)
Liquid Chromatography MS - positive - reverse-phase (1)
Liquid Chromatography MS - negative - reverse-phase (1)

Publication Date

2026 (44)
2020 (16)
2025 (15)
2023 (12)
2022 (7)
2024 (5)
2017 (5)
2021 (2)
2018 (1)

Metabolite Name

Abemaciclib (8)
Undecanedioic acid (7)
Uric acid (6)
Thymidine (6)
Inosine (6)
Desglucocoroloside (5)
Indoleacetaldehyde (5)
Enterolactone (5)
Sphingosine 1-phosphate (5)
Prolylhydroxyproline (5)
Succinic acid (5)
Taurocholic acid (5)
2-Hydroxymyristic acid (5)
16-Hydroxyhexadecanoic acid (5)
4-Hydroxybenzaldehyde (5)
Suberylglycine (5)
L-Tryptophan (5)
Hexadecanedioic acid (5)
Glutaric acid (5)
Uracil (5)
Hypoxanthine (5)
L-Threonine (5)
Xanthine (5)
Uridine (5)
1-Piperidinyloxy, 4-(((dodecyloxy)hydroxyphosphinyl)oxy)-2,2,6,6-tetramethyl- (4)
N-Arachidonoyl Methionine (4)
TetraHCA (4)
Gymnodimine (4)
Forskolin (4)
Lovastatin acid (4)

IsPrivate

False (1)

First Public Date

2026 (43)
2023 (17)
2020 (15)
2025 (11)
2022 (9)
2024 (7)
2021 (4)
2019 (3)
2017 (3)
2018 (2)

Modelling Approach

Ordinary differential equation model (1)

Study status

Active, not recruiting (1)
Recruiting (1)

Study type

Interventional (2)
RNA-seq of coding RNA from single cells (1)
RNA-seq of coding RNA (1)

Release Date

2025 (84)
2022 (56)
2024 (55)
2023 (51)
2021 (40)
2020 (33)
2019 (19)
2018 (19)
2026 (13)
2017 (10)
2016 (5)
2015 (2)

Lab affiliation

Memorial Sloan Kettering Cancer Center Department of Molecular Pharmacology (1)
Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia (1)
The Proteomics Facility of the University of Bergen (PROBE), The Department of Biomedicine, University of Bergen, Bergen, Norway (1)
Department of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA (1)
Department of Cell Biology and Physiology Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill 450 West Drive Lineberger Building CB#7295 Chapel Hill, NC, 27599, USA. Telephone: (919)-259-2695. (1)
University of Macau (1)
Department of Pharmacology and Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill (1)
IRIC-Université de Montréal (1)

Location

United States (2)

Keyword

Antineoplastic Agents, Immunological (1)
Antibodies (1)
Immunoglobulins (1)
Antibodies, Monoclonal (1)
Cetuximab (1)

Previous page
1 / 62
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 62
Next page

Sort by:

Relevance

Page size

Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits Glycogen Synthase Kinase 3 Beta and Activates WNT Signaling

The cellular and organismal phenotypic response to a small molecule kinase inhibitor is defined collectively by the inhibitor’s targets and their functions. The selectively of small molecule kinase inhibitors is commonly determined in vitro, using purified kinases and substrates. Recently, competiti...

ORGANISM(S): Homo sapiens (Human) Mus musculus (Mouse)

2017-12-07 | PXD006139 | Pride

RNA-seq of BJ human fibroblasts treated with doxorubicin or abemaciclib compared to vehicle-treated counterpart

This experiment follows the transcriptional response of human fibroblasts (BJ) to two different drug treatments (doxorubicin and abemaciclib) in comparison to treatment with vehicle (water). The two drugs are used in cancer care and their mechanism of action entails proliferative arrest. Doxorubicin...

ORGANISM(S): Homo sapiens

2021-11-29 | E-MTAB-7642 | biostudies-arrayexpress

The effects of CDK4/6 inhibitors on chemotherapy-induced senescent cells

To investigate the effects of abemaciclib (a CDK4/6 inhibitor) on the secretory phenotype (SASP) and other characteristics of chemotherapy-induced senescent cells, we performed single-cell RNA sequencing on vehicle-treated proliferating BJ fibroblasts, doxorubicin-induced senescent cells, and doxoru...

ORGANISM(S): Homo sapiens

2026-06-01 | E-MTAB-15361 | biostudies-arrayexpress

Abemaciclib differentially reshapes the immunopeptidome of breast cancer subtypes

The cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) Abemaciclib has demonstrated transformative potential in the treatment of hormone receptor-positive (HR+) breast cancer. Beyond its established role in cell cycle arrest, we reveal its capacity to enhance tumor immunogenicity by remodeling the immu...

ORGANISM(S): Homo sapiens (Human)

2026-02-25 | PXD060684 | Pride

Breast cancer Abemaciclib Tumor antigens Mass spectrometry Cancer immunotherapy Immunopeptidomics

Fra2 ChIP-seq analysis of MCF7 cells treated with abemaciclib

PRJNA660455 | ENA

JunB ChIP-seq analysis of MCF7 cells treated with abemaciclib

PRJNA660457 | ENA

RNA-seq analysis of MCF7 cells treated with abemaciclib, SR11302

PRJNA660453 | ENA

Estrogen Receptor ChIP-seq analysis of MCF7 cells treated with abemaciclib

PRJNA660449 | ENA

c-Jun ChIP-seq analysis of MCF7 cells treated with abemaciclib